Intellia Therapeutics (NTLA) Stock: Cathie Wood Continues Three-Day Buying Streak

TLDR

• Cathie Wood’s ARK Invest made only one trade on Thursday, buying 56,769 shares of Intellia Therapeutics (NTLA) worth approximately $682,000
• ARKK purchased 48,178 shares while ARKG added 8,591 shares, continuing a three-day buying streak
• Intellia stock has gained over 32% year-to-date despite falling 23% in 2025 following a patient death in a clinical trial
• The gene-editing company is advancing CRISPR-based therapies through clinical trials, including a treatment for a rare heart disease
• Analysts give NTLA a Moderate Buy rating with a price target suggesting 38% upside potential

Cathie Wood’s ARK Invest kept things simple on Thursday. The investment firm made just one trade for the entire day.

ARK purchased 56,769 shares of Intellia Therapeutics across two of its funds. The ARK Innovation ETF picked up 48,178 shares. The ARK Genomic Revolution ETF added 8,591 shares.

Intellia Therapeutics, Inc., NTLA

The total value came to roughly $682,000. News of the purchase pushed Intellia shares up more than 2% in overnight trading.

This marks the third consecutive day of ARK buying Intellia stock. On Monday, the firm acquired 99,292 shares. Tuesday saw another purchase of 40,067 shares.

Intellia operates as a clinical-stage gene editing company. The firm focuses on developing CRISPR-based therapies.

The stock has experienced volatile performance recently. Shares dropped 23% in 2025 after a patient death during a clinical trial. The male patient in his 80s was receiving an experimental treatment called Nexiguran ziclumeran.

Year-to-Date Performance Bounces Back

Despite last year’s decline, Intellia has recovered strongly in 2026. The stock has jumped over 32% since the start of the year.

Over the past 12 months, shares have climbed about 26%. Analysts attribute the gains to steady progress in gene-editing trials and growing investor interest.

The company continues to advance its lead programs through clinical testing. Nexiguran ziclumeran targets transthyretin amyloidosis with cardiomyopathy. This rare heart disease causes heart failure from faulty proteins in the heart.

Intellia ranks as ARK’s 23rd largest holding based on a December 31 regulatory filing. Within the genomic-focused ARKG fund, the company sits in the bottom five positions. Crispr Therapeutics, Tempus AI, and Guardant Health hold the top three spots in that portfolio.

Analyst Outlook Shows Confidence

Wall Street maintains a generally positive view on the stock. Nine analysts rate it a Buy, while 12 give it a Hold rating. One analyst recommends selling.

The average price target sits at $16.41. This implies potential upside of about 38% from current levels.

ARK’s continued accumulation suggests confidence in Intellia’s long-term prospects. The firm has shown consistent interest despite the clinical setback last year.

The three-day buying spree totals nearly 196,000 shares. This represents a sustained bet on the gene-editing space.

ARK’s ARKG fund specifically targets companies working on genomic technologies. The fund has been adding to its Intellia position as the company moves forward with its clinical programs.

The post Intellia Therapeutics (NTLA) Stock: Cathie Wood Continues Three-Day Buying Streak appeared first on CoinCentral.